Venetoclax Plus Rituximab can Achieve Durable Treatment-Free Remission in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Venetoclax (VEN) is a selective, potent, orally bioavailable BCL-2 inhibitor. VEN in combination with rituximab (R) is being assessed in an ongoing Phase 1b study.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Michael Choi, Danielle Brander, Andrew W. Roberts, John F. Seymour, Thomas J. Kipps, Jacqueline C. Barrientos, Matthew S. Davids, Mary Ann Anderson, Constantine Tam, Betty Prine, Carmen Cornejo, Ming Zhu, Leanne Lash, Su Young Kim, Shuo Ma Source Type: research
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia | Lymphoma | Myeloma | Rituxan | Study